Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 12/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 9/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 8/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 8/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22855796 | 0.87 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL1370561 | 0.85 | HDAC6 (0.74) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL28440243 | 0.84 | HDAC6 (0.72) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL30285347 | 0.83 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL21449136 | 0.82 | HDAC6 (0.69) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL1365734 | 0.81 | HDAC6 (0.70) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL1367216 | 0.81 | HDAC1 (0.70) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL12892562 | 0.81 | HDAC6 (0.66) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL1368416 | 0.80 | HDAC6 (0.70) | HDAC6HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL3692906 | 0.76 | HDAC6 (0.59) | HDAC6HDAC1HDAC8HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220401474-A1 | HDAC6-ACTIVATED MACROPHAGES, COMPOSITIONS, AND USES THEREOF | MEDSTAR HEALTH | 2022-12-22 | — | — | US | disclosed |
| WO-2022094319-A1 | STAT-ACTIVATED MACROPHAGES, COMPOSITIONS, AND USES THEREOF | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2020264437-A1 | HDAC6-ACTIVATED MACROPHAGES, COMPOSITIONS, AND USES THEREOF | THE GEORGE WASHINGTON UNIVERSITY (US) | 2020-12-30 | — | — | WO | disclosed |
| CN-109020921-B | Histone deacetylase HDAC6 inhibitor and preparation method and application thereof | 山东大学 | 2020-08-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401474-A1 | HDAC6-ACTIVATED MACROPHAGES, COMPOSITIONS, AND USES THEREOF | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC1 2/4885HDAC8 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.